课题基金 / 基金详情

Intranasal Deferoxamine to Precondition Against Stroke

Intranasal Deferoxamine to Precondition Against Stroke
鼻内去铁胺预防中风
批准号:
6870096
负责人:
Samuel Scott Panter
金额:
$22.65万
依托单位国家:
美国
项目类别:
财政年份:
2005
资助国家:
美国
项目状态:
已结题
起止时间:
2005-01-24 至 2006-11-30

项目摘要

项目成果

Samuel Scott Panter的其他基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): Coronary artery bypass graft (CABG) surgery is a procedure after which patients manifest significant neurological dysfunction, including stroke and cognitive impairment. In fact, patients in high-risk groups have an incidence of adverse cerebral outcome greater than 16%. The studies of this proposal are directed toward a model that utilizes a technique that may reduce perisurgical neurological problem by preconditioning the brain to be more resistant to ischemic insults. We will try to accomplish this goal using a rat model of middle cerebral artery occlusion (MCAO), and we will attempt to precondition using a unique drug delivery system-intranasal. The drug we have chosen to use-deferoxamine (DFO)-has been demonstrated to precondition in a number of experimental systems, from cell culture to neonatal animals to adult animals. The administration of DFO in these studies provided protection from ischemia; however, the parenteral administration of DFO is problematic because of its short half-life and side-effects. The experiments of this proposal will utilize intranasal deli very of DFO in rats. First, intranasal deli very will documented using DFO radio labeled with a small quantity of ferric 59Fe, and the amount of DFO in brain will be determined qualitatively and quantitatively. Second, a dose-response relationship for the induction of HIF1alpha and its endurance over time will be determined. Third, at the time point of maximal HIF-1 alpha induction, a MCAO will be performed and neurological outcome and infarct size will be assessed. Our preliminary studies indicate that three doses of intranasal DFO, three hours apart, significantly up-regulate the concentration of HIF-1alpha in brain 48 hours later. When a MCAO is performed at this time point, a 65% reduction in infarct size was observed. These studies may yield data that could be translated into the clinic and eventually provide neuroprotection to patients undergoing procedures that put them at risk for neurological injury, such as CABG surgery.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Intranasal deferoxamine to treat stroke in young and older, male and female rats
Intranasal deferoxamine to treat stroke in young and older, male and female rats
Intranasal deferoxamine to treat stroke in young and older, male and female rats
Intranasal Deferoxamine to Precondition Against Stroke